Lakefront Biotherapeutics NV current report, Q4 FY2025

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of November 2025. The filing incorporates by reference a press release dated November 3, 2025 (Exhibit 99.1). The registrant's principal executive office is located in Mechelen, Belgium. The filing confirms the company files annual reports on Form 20-F.

Financial Metrics

The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document. The filing serves solely to distribute the attached press release.

Material Changes

The filing text does not disclose specific material changes in financial position or operations compared to prior periods. The content is limited to the procedural incorporation of the November 3, 2025, press release.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, financial guidance, or specific risk factors. It notes that the press release includes quotes from Omotayo Fasan, but the content of those quotes is not detailed in the Form 6-K text itself.

Key Facts for Investor Verification

  • Company Identity: Verify that the filing is for Galapagos NV, not Lakefront Biotherapeutics NV (the latter appears to be an error in the request metadata).
  • Press Release Content: Review Exhibit 99.1 (the press release) directly, as the Form 6-K text only references it without summarizing its substance.
  • Financial Data: No financial metrics are present in this filing; investors must refer to the most recent Form 20-F or quarterly reports for financial status.
  • Registration Statements: The press release is incorporated by reference into multiple Form S-8 registration statements.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.